Precision Business Insights has published a report on the global radioligand therapy market, estimating its value at USD 8,471.2 million in 2024 and is expected to expand at a compound annual growth rate (CAGR) of 7.6% over the forecast period 2025-2031. The report explores the market growth and potential opportunities in the market industry. Additionally, it offers a detailed analysis of how these elements will affect market demand dynamics and market performance throughout the forecast period.

View the detailed report description here - https://www.precisionbusinessinsights.com/market-reports/radioligand-therapy-market      

Radioligand therapy is a precision cancer treatment that uses radioactive isotopes attached to targeting molecules (ligands) to deliver radiation directly to cancer cells. This approach minimizes damage to surrounding healthy tissue and is part of a broader class of radiopharmaceuticals.

The market is primarily driven by the rising prevalence of cancer, particularly prostate cancer and neuroendocrine tumors, which has increased the demand for targeted treatment options. Growing awareness and adoption of precision medicine, along with the advantages of radioligand therapy such as minimal side effects and higher specificity compared to conventional chemotherapy, are fueling market growth.  

The global radioligand therapy market segmentation:
1) By Brand: Cadent iTero, 3M ESPE Lava COS, CEREC, E4D, TRIOS, CS, and Others
2) By Modality: Standalone, Portable and Others
3) End User: Hospitals, Dental Clinics and Others.

Request sample report at https://www.precisionbusinessinsights.com/request-sample/?product_id=369061

Regional Overview:
The report also examines the current concerns and their Future Effects on the radioligand therapy market by the region. The market has been segmented into numerous primary regions and a detailed evaluation of primary countries.

• North America (U.S., Canada)
• Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
• Asia-Pacific (China, India, Japan, Australia, Southeast Asia, Rest of Asia Pacific)
• Latin America (Mexico, Brazil, Argentina, Columbia, Rest of Latin America)
• Middle East & Africa (GCC, Egypt, Nigeria, South Africa, Rest of Middle East and Africa)

The competitive landscape is dominated by major players like Novartis AG, Bayer AG, Curium Pharma, Telix Pharmaceuticals, POINT Biopharma, RayzeBio, Fusion Pharmaceuticals, NorthStar Medical Radioisotopes, ITM Isotope Technologies, Munich SE, Lantheus Holdings Inc.

About Precision Business Insights:
We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.

Precision Business Insights offers a variety of cost-effective and customized research services to meet research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.

Contact:
Mr. Satya
Precision Business Insights | Toll Free: +1 866 598 1553
Email: sales@precisionbusinessinsights.com
Kemp House, 152 – 160 City Road, London EC1V 2NX
Web: https://precisionbusinessinsights.com/ | D U N S® Number: 852781747